louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02590536: A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
Official title: A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Fetal Growth Retardation
Keywords: Sildenafil
Fetal growth Restriction
Umbilical Artery Doppler
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2015-10-29
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Randomized Controlled Trial to evaluate the effect of sildenafil on Doppler velocity indices of the umbilical arteries in patients with placental insufficiency and fetal growth restriction, and if sildenafil can improve fetal and neonatal outcomes in those patients.


Eligibility criteria: Inclusion Criteria:

* Pregnant women, singleton pregnancy, gestational age 24-34 weeks, with

  * Fetal growth restriction.
  * Intact membranes.
  * Abnormal umbilical artery Doppler waveforms.
* Fetal abdominal circumference at or below the tenth percentile.
* Normal venous fetal Doppler

Exclusion Criteria:

* Undetermined gestational age.
* Intrauterine infection.
* High Risk for aneuploidy (e.g. maternal age ≥40 years, detected congenital fetal anomalies in the current or previous pregnancies).
* Maternal cardiovascular morbidity.
* Users of any vasodilator agents.
* Known allergy to sildenafil citrate

Primary outcomes:
measure: The change in Doppler velocity indices( Resistance index (RI) and the pulsatility index (PI) of the umbilical arteries as a Ratio
timeFrame: 24 weeks to 34 weeks of gestation.
measure: The change in Doppler velocity indices( Resistance index (RI) and the pulsatility index (PI), of fetal middle cerebral artery as a Ratio
timeFrame: 24 weeks to 34 weeks of gestation.
Secondary outcomes:
measure: Neonatal birth weight in grams
timeFrame: At time of Delivery
measure: Gestational age at delivery in weeks
timeFrame: At time of Delivery
measure: Neonatal complication rates including Intraventricular hemorrhage (IVH) , Neonatal Necrotizing Enterocolitis (NEC) , Syndrome Respiratory Distress (RDS) , Neonatal anemia, Neonatal blood transfusion).
timeFrame: The first 28 day of delivery
measure: Neonatal ICU admission rate
timeFrame: The first 28 day of delivery
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain shams university maternity hospital
Study officials:
affiliation: Ain Shams University
name: Khaled I Abdullah, MD
role: STUDY_CHAIR
affiliation: Ain Shams University
name: Sherif A Ashoush, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ain Shams University
name: Heba E Hosney, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04990336: Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
Official title: Comparison of Clinical Efficacy of Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acute Pancreatitis
Keywords: Acute Pancreatitis
Dachaihu Decoction Compound
Rhubarb Single Medicine
Lead sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2021-08-04
Enrollment: 306
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.


Eligibility criteria: Inclusion Criteria:

* Age from 18 to 65 years old
* Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset
* Consent of the subjects, who sign the informed consent form

Exclusion Criteria:

* Women who are pregnant or breastfeeding
* Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.
* Patients with a history of severe heart, liver, kidney and other important organ diseases
* Patients with mental illness and malignant tumors
* People who have allergies, or are allergic to a certain drug ingredient

Primary outcomes:
measure: Significant and effective rate
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06452836: Colors, Can They Reduce the Dental Anxiety
Official title: Colors, Can They Reduce the Dental Anxiety
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Anxiety
Anxiety State
Tooth Extraction Status Nos
Lead sponsor: Selcuk University
Sponsor class: OTHER
First posted: 2024-06-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigator's aim in this study was to evaluate the preoperative anxiety and pain felt during the operation due to exposure to green, red, and blue light. For this purpose, the participants will wear colored glasses before the operation. The investigator will evaluate the patient's anxiety change and the pain she/he feels during the procedure.


Eligibility criteria: Inclusion Criteria:

* ASA 1 and ASA 2 patient population
* not having had a third molar surgery before
* volunteer to participate in the study

Exclusion Criteria:

* dental phobia
* patients who will be treated under general anesthesia
* refusing the measurements
* not filling out the VAS
* encountering complications during surgery
* operations lasting more than 45 minutes

Primary outcomes:
measure: Change in the Anxiety Score
timeFrame: 1 minute after the participant sits the dental unit and 10 minutes after
Secondary outcomes:
measure: Change in the oxygen saturation
timeFrame: 1 minute after the participant sits the dental unit and 10 minutes after
measure: Change in the pulsation
timeFrame: 1 minute after the participant sits the dental unit and 10 minutes after
measure: Intraoperative Pain Score
timeFrame: 1 minutes after the surgery
measure: Change in the salivary cortisol level
timeFrame: 1 minute after the participant sits the dental unit and 10 minutes after
measure: Change in the salivary alfa-amilase level
timeFrame: 1 minute after the participant sits the dental unit and 10 minutes after
Other outcomes:
Locations:
city: Konya
country: Turkey
facility: Selcuk University, Faculty of Dentistry
state: Selçuklu
Study officials:
affiliation: Selcuk University, Faculty of Dentistry
name: Gökhan Gürses
role: STUDY_CHAIR
affiliation: Selcuk University, Faculty of Medicine
name: İsmail Okumuş
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06176417: Comparison Between Different Horizontal Ridge Augmentation Techniques
Official title: Horizontal Ridge Augmentation Using Decompression Technique Versus Ridge Splitting in Atrophic Posterior Mandibular Ridge With Simultaneous Implant Placement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrophic Ridge
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2023-12-19
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sixteen patients were selected from the Outpatient Clinic of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University for replacement of missed single tooth / teeth in posterior atrophic mandible by dental implant.

Patients' grouping:

Patients were divided randomly into two equal uniform groups as follow:

Group I:

Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by decompression technique.

Group II:

Eight implants were placed in patients of missing single tooth / teeth in posterior mandible with subsequent horizontal ridge augmentation by ridge splitting technique using piezosurgery.

All patients were evaluated clinically and radiographically at regular time interval immediately, 6 and 12 months after surgery.


Eligibility criteria: Inclusion Criteria:

* Patient's cooperation, motivation and good oral hygiene.
* Patient medically free from systemic diseases that absolutely contraindicate implant surgery.
* Moderately atrophic posterior mandible (horizontal alveolar dimension is not more than 4 mm at the crest), with minimum 10 mm vertical height.
* Patients prepared to comply with the follow-up and maintenance programme.
* Free from history of bruxism / parafunctional habits.

Exclusion Criteria:

* Patients with local pathological disease such as cyst, tumor at the planned surgical site.
* Pregnant patients.
* Heavy smoker patients.

Primary outcomes:
measure: Alveolar ridge width
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Sara Elmagraby
Study officials:
References:
Clinical trial NCT05544617: Recurrent Collection By Medical Student in General Medicine
Official title: Recurrent Collection By Medical Student From Sorbonne-Université in General Medicine
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: General Practice
Keywords: citizen science
Medical student
ICPC
Lead sponsor: Sorbonne University
Sponsor class: OTHER
First posted: 2022-09-16
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: iterations of group of 5 consecutive patients consulting a general practice, regardless of the reason for consultation

Brief summary: The project for the recurrent collection of data from interns in general medicine is a formalized description of the consultations attended by medical students during their outpatient training. This formalization uses the International Classification of Primary Care. This project aims to create a research network between general medical interns, mainly for their thesis, which pools their observations in a database accessible to all participants.


Eligibility criteria: Inclusion Criteria:

* consultation of his general practitioner

Exclusion Criteria:

* None

Primary outcomes:
measure: reason for consultation
timeFrame: through study completion, an average of 6 month
measure: diagnosis
timeFrame: through study completion, an average of 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Avon
country: France
facility: guillaume AVENIN
Study officials:
References:
Clinical trial NCT05737017: The Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet)
Official title: A Randomized Active-controlled Clinical Trial to Investigate the Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet) During Endoscopic Resection for Colorectal Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Colonic Polyps
Lead sponsor: Seoul St. Mary's Hospital
Sponsor class: OTHER
First posted: 2023-02-21
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure. In this study, the investigators examine the hemostatic effect of ClearCoajet on intraprocedural bleeding during endoscopic mucosal resection or endoscopic submucosal dissection for colorectal sessile polyps or lateral growth tumors larger than 1.5 cm. The investigators also aim to compare the delayed bleeding and recurrence rates between the ClearCoajet group and the control group.


Eligibility criteria: Inclusion Criteria:

* patients with colorectal sessile polyps or lateral growth tumors larger than 1.5 cm

Exclusion Criteria:

* Pedunculated polyp
* Patients with coagulopathy

Primary outcomes:
measure: Hemostasis of intraprocedural bleeding
timeFrame: during endoscopic resection for colorectal lesions
Secondary outcomes:
measure: Delayed bleeding rate
timeFrame: within 4 weeks after endoscopic resection
measure: Complication rate
timeFrame: within 4 weeks after endoscopic resection
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yeouido St. Mary's Hospital
Study officials:
References:
Clinical trial NCT01788917: Effects of Supplementation With Linseed Oil on Blood Lipids in Vegetarians
Official title: Effects of Supplementation With Linseed Oil on Blood Lipids and Fatty Acid Profile in Plasma and Erythrocyte Lipids in Vegetarians
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inter-conversion n-3 PUFA, Vegetarians
Keywords: n-3 LC-PUFA, vegetarians, fatty acids, blood lipids
Lead sponsor: University of Jena
Sponsor class: OTHER
First posted: 2013-02-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study was performed to investigate the effects of a daily consumption of linseed oil on fatty acid distribution in plasma and red blood cell lipids and blood lipids in vegetarians.

Detailed description: Recent studies suggest that the daily intake of n-3 LC-PUFA (EPA and DHA) can modulate cardiovascular risk factors and prevent lifestyle diseases.

The major dietary source of EPA and DHA is seafood (seaweeds and fatty cold water fishes), but they can also be found in lean red meat, in organ meats such as liver and brain. Vegetarians who do not eat meat or fish, have very low or negligible intakes of EPA (\< 5 mg EPA/d) and DHA.

The purpose of the present study is to explore the tissue distribution and inter-conversion of ALA to n-3 LC-PUFA as consequence of linseed oil supplementation in vegetarians.

Eight vegetarians (3 m; 5 f) who do not eat meat, fish or seaweeds such as algae foods since least two years ago and two subjects (1 m; 1w) who consume the normal western style diet living in Jena (Germany) entered the study. The participants consumed 10 mL linseed oil per day for 10 weeks. The resulting daily dose of ALA was approx. 5.7 g/d.

Eligibility criteria: Inclusion Criteria:

* for the vegetarian sub-group : vegetarian diet pattern

Exclusion Criteria:

* high performance sport, daily alcohol intake and the in-take of dietary supplements (e.g., fish oil capsules)
* for the vegetarian sub-group, the consumption of fish and algae products (e.g. seaweeds, sushi)

Primary outcomes:
measure: EPA concentrations in plasma lipids and red blood cell lipids
timeFrame: 10 weeks
Secondary outcomes:
measure: blood lipids
timeFrame: 10 weeks
Other outcomes:
measure: parameters of iron status
timeFrame: 10 weeks
Locations:
Study officials:
References:
Clinical trial NCT01258517: The Effect of Surfactant Administration on Cerebral Oxygenation
Official title: The Effect of the Type and the Method of Surfactant Administration on Oxygenation in Preterm Infants: a Near Infrared Spectroscopy Study
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Respiratory Distress Syndrome
Prematurity
Keywords: RDS
surfactant
cerebral oxygenation
near infrared spectroscopy
Lead sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor class: OTHER
First posted: 2010-12-13
Enrollment: 40
Sex: ALL
Minimum age (years): 23
Maximum age (years): 32
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: \<32 week or \<1500 g required surfactant treatment for established RDS

Brief summary: The purpose of this study is to assess changes in cerebral oxygenation during two different types (beractant and poractant) and two different routes (double lumen or single lumen endotracheal tube) of surfactant administration using near infrared spectroscopy (NIRS).


Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of respiratory distress syndrome \<32 gestational weeks and/or \<1500 g birthweight

Exclusion Criteria:

major congenital anomalies complex congenital heart diseases

Primary outcomes:
measure: to determine the optimal and the most safe surfactant administration technique with regard to cerebral oxygenation as measured by near infrared spectroscopy in low birth weigh infants
timeFrame: up to 36 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Zekai Tahir Burak Maternity Teaching Hospital, Neonatal Intensive Care Unit
Study officials:
References:
Clinical trial NCT04656717: Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice
Official title: Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice: a Nationwide French Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: Next-generation sequencing (NGS)
Cost
Cancer diagnosis
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2020-12-07
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: French laboratories (7 somatic genetics and 8 germline oncogenetic) currently performing NGS.The laboratories were chosen because they performed cancer diagnostics nationwide and presented the full spectrum of clinical indications and technical solutions

Brief summary: The aim of this study was to measure the total cost of performing next-generation sequencing (NGS) in clinical practice in France, in both germline and somatic cancer genetics.

The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps was used.

Additional non-specific costs were also included and costs were detailed per step of the process.


Eligibility criteria: Inclusion Criteria:

* French genetics laboratories performing somatic and germline clinical NGS tests.

Exclusion Criteria:

-

Primary outcomes:
measure: Overall production cost
timeFrame: through study completion, an average of 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06969417: Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
Official title: Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Herpes Zoster (HZ)
Post Herpetic Neuralgia (PHN)
Lead sponsor: CMH Kharian Medical College
Sponsor class: OTHER_GOV
First posted: 2025-05-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities.

Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.

Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.


Eligibility criteria: Inclusion Criteria:

* Diagnosed cases of herpes zoster suffering from postherpetic neuralgia
* Ages: 18 to 50
* Both male and female

Exclusion Criteria:

* Lack of consent
* Patient already taking pain killers for post herpetic neuralgia
* Patients suffering from other systemic illness

Primary outcomes:
measure: Visual Analog Scale
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kharan
country: Pakistan
facility: CMH Kharian Medical College
state: Punjab
Study officials:
affiliation: CMH Kharian Medical College
name: Usman Nawaz, MBBS, Mphil, PhD Pharmacology
role: STUDY_CHAIR
References: